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Abstract: The aim of this study was to find signs of progress in the pharmacotherapy of chronic 
pain over the past 35 years using scientometric analysis. The following scientometric indices 
were used: 1) popularity index, representing the share of articles on a specific drug(s) relative 
to all articles in the field of chronic pain; 2) index of change, representing the degree of growth 
in publications on a topic from one period to the next; 3) index of expectations, representing the 
ratio of the number of articles on a topic in the top 20 journals relative to the number of articles 
in all (.5,000) biomedical journals covered by PubMed; and 4) index of ultimate success, 
representing a publication outcome when a new drug takes the place of a common drug previ-
ously used for the same purpose. Publications on 55 drugs used in the treatment of chronic pain 
were assessed during seven 5-year periods, from 1979 to 2013. The rate of rise in the number of 
publications on chronic pain was exponential, with an increase of nearly ninefold from 2,346 
articles over the 5-year period 1979–1983 to 21,095 articles in 2009–2013. However, despite this 
huge increase in publications, our scientometric analysis did not reveal signs of really successful 
drugs in this field. For the 2009–2013 period, the popularity index had a meaningful magnitude 
(from 0.5–2.8) for only 13 of 55 drugs. Five of them were opioids, including morphine, which 
had the highest index value of all drugs (2.8). None of the drugs had a high index of expectations 
in 2009–2013. The index of ultimate success was positive only with triptans in the relatively 
limited area of acute treatment of migraine. As a result, despite rapid growth in the number of 
publications, our scientometric analysis did not reveal signs of substantial progress in the field 
of pharmacotherapy for chronic pain.
Keywords: anticonvulsants, antidepressants, headache, lower-back pain, migraine, neuropathic 
pain, NSAIDs, opioids, osteoarthritis, postherpetic neuralgia, triptans
Introduction
A recent report from the US Institute of Medicine’s Committee on Pain Relief indicated 
that more than 116 million Americans (about 37% of the population) have pain that 
persists for weeks to years. The most significant costs of this epidemic are associated 
with chronic pain,1 which is one of the most widely cited conditions underlying dis-
ability among older adults.2
The scientometric assessments of drugs have been reported previously in a number 
of publications.3–7 Some of the indices based on such assessments were suggested as 
signs demonstrating progress in the pharmacotherapy of pain. The link between the 
number of publications and progress in pharmacotherapy is inherently weak. It is 
enough to mention that the mere number of publications does not differentiate between 
publications characterizing a drug in positive and negative ways. Sometimes after a Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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drug introduction, due to the possible discovery of unex-
pected adverse effects, a significant number of articles can be 
devoted to the problems associated with its administration.6 
Nevertheless, some of the scientometric indices can be used 
to indicate certain changes in the related pharmacotherapy. 
Such indices may provide an additional support to the con-
clusions based on good-quality evidence obtained with ran-
domized controlled trials. The aim of the current study was 
to find signs of progress in the pharmacotherapy of chronic 
pain using scientometric analysis.
Materials and methods
The following publication parameters3–7 were used as signs 
of progress in the pharmacotherapy of chronic pain.
Popularity index
The popularity index (PI) is the share of articles on a spe-
cific topic relative to all articles in the field of chronic pain 
(chronic pain OR neuropathic pain OR neuralgia OR head-
ache disorders [Medical Subject Headings {MeSH} term]). 
A specific threshold of 0.5% (arbitrary) was used to select 
topics for which the number of publications (2009–2013) 
reached a notable level.
index of change
The index of change (IC) is the change in number of publica-
tions on a drug during a 5-year period compared to the previ-
ous 5-year period. It reflects the change in general interest 
in a topic. The specific threshold used for this index was the 
growth beyond the increase in number of publications in the 
whole field of chronic pain during the same time interval.
index of expectations
The index of expectations (IE) or top journal selectivity 
index, is the ratio of the number of all types of articles on a 
particular topic in the top 20 journals relative to the number 
of articles in all (.5,000) biomedical journals covered by 
PubMed over 5 years. It reflects the level of interest in a topic 
in the top journals. An index value $10 was selected to rep-
resent a high expectation of success. The 20 top journals were 
selected based on two factors: 1) their rank sorted by impact 
factor, as indicated by Journal Citation Reports for 2012; and 
2) the journal’s specialty area. They included pharmacology, 
anesthesiology, pain, neurology (ten journals), and general 
biomedical journals (also ten): Anesthesiology, Annals of 
Internal Medicine, Annals of Neurology, British Journal of 
Anaesthesia, British   Medical Journal, Journal of the   American 
Medical Association, Journal of   Clinical Investigation, 
Journal of Clinical   Pharmacology and Therapeutics, Journal 
of Pharmacology and   Experimental Therapeutics, Lancet, 
Lancet –   Neurology, Nature, Nature – Medicine, Nature 
Reviews – Drug   Discovery, Nature Reviews – Neuroscience, 
New England Journal of   Medicine, Pain, Proceedings of the 
National Academy of Science of the United States of America, 
Science, and Trends in Pharmacological Sciences.
index of ultimate success
The index of ultimate success (IUS) is a publication outcome 
indicating that a new drug (or a group of drugs) has taken 
the place of a drug that was previously commonly used for 
the same purpose. It is measured by the degree of decline 
in the PI of an old, supplanted drug. A decline of the PI of 
a supplanted drug by 50% or more during an interval of 
10–20 years was selected to represent a positive IUS.
The articles were counted using the National Library of 
Medicine’s PubMed website (http://www.ncbi.nlm.nih.gov/
pubmed), which covers over 21 million journal articles in 
  biomedicine. Drugs used for the treatment of chronic pain 
were selected from various sources.8–15 The following 55 drugs 
were searched: acetaminophen, almotriptan, amitriptyline, 
aspirin, atenolol, buprenorphine, carbamazepine, celecoxib, 
clonazepam, codeine, desipramine, diclofenac, dihydro-
ergotamine, divalproex, doxepin, dronabinol, duloxetine, 
eletriptan, ergotamine, flunarizine, fluoxetine, flurbiprofen, 
frovatriptan, gabapentin, hydrocodone, hydromorphone, ibu-
profen, imipramine, indomethacin, ketoprofen, lamotrigine, 
methadone, methysergide, mexiletine, morphine, nalbuphine, 
naproxen, naratriptan, oxycodone, phenytoin, piroxicam, 
pregabalin, propranolol, rizatriptan, sumatriptan, tapentadol, 
timolol, topical capsaicin, topiramate, tramadol, transdermal 
fentanyl, venlafaxine, verapamil, ziconotide, and zolmitriptan 
(MeSH terms indicated in Table 1). The criterion for selec-
tion of a particular drug for analysis was the level of its PI in 
2009–2013. If the PI was .0.5, the drug was assessed using 
the IC, IE, and IUS.
An individual drug name or the name of a class of drugs 
(such as anticonvulsants [MeSH term], antidepressants, 
opioids, or NSAIDs [nonsteroidal anti-inflammatory drugs]) 
was entered in the search box with the following keyword 
combination: chronic pain OR neuropathic pain OR neural-
gia OR headache disorders (MeSH term). In addition to the 
terms related to the main field of chronic pain, several related 
specific subfields (areas) were assessed separately. As a 
result, the following keywords or keyword combinations were 
entered in the search box: migraine, postherpetic neuralgia, 
osteoarthritis (AND pain), or low back pain (MeSH term). Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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Filters for languages (English) were used. All types of articles 
were taken into account.
Results
Of 55 drugs used in chronic pain management and included 
in the search, the 13 with a PI .0.5% (in 2009–2013) are 
presented in Table 1. Five of them are opioids, four drugs 
are anticonvulsants, and the rest are two antidepressants, one 
NSAID, and acetaminophen. Seventeen of the 55 included in 
the search drugs had PIs between 0.5 and 0.1, including six 
NSAIDs and four opioids. During 2009–2013, none of the 
drugs listed in Table 1 demonstrated an IE of $10.   During 
the same period, only four drugs had notable increases in 
the IC (above the increases in the whole field of chronic pain): 
pregabalin, oxycodone, duloxetine, and codeine.
The relative roles of major classes of drugs in several 
specific subfields (areas) of chronic pain are presented in 
Table 2. Although opioids, NSAIDs, anticonvulsants, and 
antidepressants may be used in all areas of chronic pain, their 
predominant applications are rather specific. For example, let 
us compare postherpetic neuralgia and osteoarthritis pain. In 
2009–2013, the PI of anticonvulsants for postherpetic neural-
gia reached 20.3, but was only 0.5 for pain in osteoarthritis. 
Conversely, the PI of NSAIDs in osteoarthritis was 9.0, but 
only 3.3 in postherpetic neuralgia. The only class of drugs 
that was used very selectively is triptans, mostly as abor-
tive medications for the treatment of migraine. Therefore, 
the 2009–2013 PI of drugs for the treatment of migraine is 
presented separately in Table 3. Sumatriptan’s PI was the 
highest – 4.5 – and six other triptans had PIs ranging from 
1.1 (rizatriptan) to 0.4 (eletriptan). Along with triptans, three 
anticonvulsants (topiramate, PI 4.0; divalproex, PI 1.7; and 
gabapentin, PI 0.6), three NSAIDs (naproxen, PI 1.0; aspirin, 
PI 0.9; and ibuprofen, PI 0.6), and acetaminophen (PI 0.9) 
appeared most often in migraine-related publications.
The 1979–2013 time course of PIs for major classes of 
drugs used for the treatment of chronic pain is presented in 
Figure 1. Over the past 35 years, there have been no impor-
tant changes in PI for anticonvulsants, antidepressants, or 
NSAIDs. NSAIDs had a PI of 3.4 in the first 5-year period 
(1979–1983), and 3.5 in the most recent period (2009–2013). 
PI for antidepressants declined, though only by about 30%, 
from 4.7 (1979–1983) to 3.5 (1989–1993) and then to 
3.3 (2009–2013). Specifically, amitriptyline’s PI declined 
from 1.1 (1984–1988) to 0.8 (2009–2013). The PI for anticon-
vulsants was 3.7 in 1979–1983, and in 2004–2008 it increased 
to 7.0; however, it then declined to 5.0 in 2009–2013. 
The aforementioned relative stability of PI is especially Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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impressive if the rate of growth in the number of articles 
related to chronic pain is taken into account. As indicated in 
Figure 1 and stated earlier, from 1979–1983 to 2009–2013, 
the number of articles per 5-year period increased ninefold. 
The most significant change in the PI reflected by Figure 1 
was the continuous rise in the PI of opioids: from 4.1 in 
1989–1993 to 9.2 in 2009–2013.
The time course of PI for triptans, a class of drugs used 
predominantly for abortive treatment of migraine, is pre-
sented in Table 4. In 1999–2003, the PI of triptans reached 
19.9 among migraine-related articles, after which it declined, 
but not below 10.3 (2009–2013). Two drugs that before the 
introduction of triptans were used for abortive therapy of 
migraine – ergotamine and dihydroergotamine – showed 
a dramatic decrease in combined PI: from 10.0 and 8.2 
(1974–1978 and 1979–1983) to 1.8 (2009–2013). At the 
same time, the PI of anticonvulsants, drugs used for migraine 
prevention, did not decline with the introduction of triptans 
(Table 4).
Selective decline in the PI of supplanted drugs can be 
regarded as the most reliable indication of success of a 
new, supplanting agent(s) and can be measured by the IUS. 
In the 15 years after the introduction of triptans, their IUS 
reached 67% (the decline of ergotamine/dihydroergotamine 
PI). Table 5 presents the IUS of triptans in comparison with 
several other classes of drugs (proton-pump inhibitors, 
  angiotensin-converting enzyme inhibitors, and triazole 
antifungal drugs). The table indicates that it usually takes 
10–15 years to achieve an IUS of 50 or more.
Table 6 represents the 1979–2013 time course of changes 
(IC) in publications on chronic pain 1) in general and 2) 
in the specific migraine area, and 3) compares them with 
changes in all medicobiological publications covered by 
PubMed in an article-type category – “journal article”. The 
table clearly indicates that publication efforts in the field of 
chronic pain did not lag behind that in all medicobiological 
areas (combined) in any of the eight 5-year periods starting 
with 1979–1983. In most time periods, IC was significantly 
higher than that with all medicobiological publications in 
general, and its 5-year increases varied from a minimum 
of 24 (1989–1993) to a maximum of 66 (1999–2003). It is 
also of interest that for the two 5-year periods preceding the 
discovery of triptans (1979–1983 and 1984–1988), the IC 
for migraine-specific publications was not higher than for 
the chronic pain field in general.
Discussion
Popularity index
The results indicate that among drugs used for the treatment 
of chronic pain, morphine was the subject of the highest 
number of current publications. In 2009–2013, the share of 
Table 3 2009–2013 popularity index of drugs for treatment of 
migraine
Name Number  
of articles
Popularity 
index (%)*
sumatriptan# 277 4.5
Topiramate 246 4.0
Divalproex 104 1.7
amitriptyline# 67 1.1
Dihydroergotamine# 67 1.1
Rizatriptan 66 1.1
Propranolol# 65 1.1
naproxen# 61 1.0
ergotamine# 58 1.0
aspirin# 57 0.9
Zolmitriptan 57 0.9
acetaminophen# 54 0.9
almotriptan 52 0.8
Frovatriptan 50 0.8
Flunarizine 40 0.6
gabapentin 39 0.6
ibuprofen# 36 0.6
naratriptan 29 0.5
Notes: *Share of all (6,111) migraine-subfield publications in 2009–2013;  #Mesh 
term. The  following  drugs  did  not  reach  the 2 008–2013  threshold  of 0 .5%  for 
the whole subfield of migraine: eletriptan 0.4, lamotrigine 0.4, carbamazepine 0.4, 
verapamil 0 .4,  metoprolol 0 .3,  methysergide 0 .2,  timolol 0 .2,  fluoxetine 0 .2, 
pregabalin 0.2, atenolol 0.1.
Abbreviation: Mesh, Medical subject headings.
Table 2 2009–2013 popularity index for major classes of drugs used in different subfields of chronic pain
Migraine Postherpetic  
neuralgia
Osteoarthritis  
AND pain
Lower-back 
pain
Popularity index (%)
  Opioids 1.6 9.5 4.0 3.5
  nsaiDs (OR acetaminophen) 4.2 3.3 9.0 2.4
  anticonvulsants 5.5 20.3 0.5 0.5
  antidepressants 1.8 4.8 0.7 0.7
  Triptans 10.3 – – –
Total number of pain-subfield articles 6,111 518 5,302 6,213
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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articles related to this drug was 2.8% of articles published 
in the whole field of chronic pain (PI 2.8). Although this 
number is much lower than that associated with the morphine 
PI for the treatment of acute pain – 11.67 – the persistence 
of morphine as the most popular drug in the field of chronic 
pain can only be regarded as a sign of failure of progress in 
the pharmacotherapy of chronic pain. Systematic reviews on 
opioid treatment of chronic nonmalignant pain have found 
insufficient evidence to make a conclusion on the long-term 
efficacy of such treatment.16–19 In addition, even in relatively 
short-term therapy, opioids are not sufficiently effective. For 
example, in the treatment of neuropathic pain, the $50% 
number-needed-to-treat index of opioids is approximately 
2.5.20 That means that only one of two or three patients 
will achieve pain relief, and that relief will be only partial. 
The other important problem in the use of opioids for chronic 
pain is their safety, especially in terms of risk of addiction 
and overdose death, which was clearly neglected.21 The US 
Food and Drug Administration (FDA) even created its Risk 
Evaluation and Mitigation Strategies for opioids to deal with 
potential safety problems.22
Although opioids have been used for the treatment of 
persistent pain for centuries, in 1960–1980 they were used for 
chronic nonmalignant pain infrequently.23 This explains the 
almost-complete absence of publications on the use of mor-
phine for chronic pain before 1983. However, in the 1990s, 
as indicated in Table 1, the number of morphine-related 
articles increased rather dramatically. The other indication of 
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Table 4 1979–2013 time course of popularity index (Pi) for major classes of drugs used for treatment of migraine
Years Number of  
all migraine- 
related articles
Drug-related articles
Triptans Ergotamine OR 
dihydroergotamine
NSAIDs OR 
acetaminophen
Anticonvulsants
Number PI (%)
Number PI (%) Number PI (%) Number PI (%)
1974–1978 758 – – 76 10.0 33 4.4 19 2.5
1979–1983 1,018 – – 84 8.2 54 5.3 20 2.0
1984–1988 1,370 47 3.4 86 6.3 83 6.1 79 5.8
1989–1993 1,740 204 11.7 117 6.7 109 6.3 64 3.7
1994–1998 2,371 445 18.8 136 5.7 131 5.5 100 4.2
1999–2003 3,526 701 19.9 131 3.7 202 5.7 179 5.1
2004–2008 5,077 742 14.6 113 2.2 249 4.9 356 7.0
2009–2013 6,111 629 10.3 109 1.8 260 4.2 334 5.5
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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the rise in popularity of opioids for the treatment of chronic 
pain is the number of opioids with PIs .0.5: of 13 drugs at 
that level, five are opioids. All of them except tramadol were 
introduced more than 50 years ago. Figure 1, which presents 
the time course of PI for opioids as a class of drug in general, 
also confirms continuous growth in the popularity of opioids 
for the treatment of chronic pain.
Table 1 indicates that three drugs with high PIs 
(but lower than that of morphine) are anticonvulsants: 
gabapentin, pregabalin, and topiramate (PIs of 2.3, 1.9, 
and 1.0, respectively). Figure 1 shows that the popular-
ity of anticonvulsants in general rose in 1999–2003 and 
2004–2008 (with PIs of 6.0 and 7.0, respectively) and then 
declined to 5.0 in 2009–2013 (almost the same level as 
anticonvulsants had in 1984–1988). The rise in the PI of 
anticonvulsants in 1999–2003 and 2004–2008 coincided 
with the FDA approval of three anticonvulsants for indi-
cations related to some types of chronic pain (gabapentin 
in 2002, pregabalin in 2004, and topiramate in 2004). 
Duloxetine and amitriptyline are two antidepressants with 
a PI higher than 0.5 (Table 1). Because triptans were used 
mostly for migraine, the PI for migraine-related articles was 
determined separately. Table 3 indicates that in 2009–2013, 
sumatriptan had the highest number of publications – PI 4.5. 
Six other triptans had much lower popularity: the PI varied 
from 1.1 (rizatriptan) to 0.4 (eletriptan).
indices of expectations and change
The IE reflects expectations regarding a drug’s prospects. 
In 2009–2013, none of the 13 most popular drugs had 
an IE higher than 10 (Table 1), and only four had an IE 
above 6: morphine (9.7), duloxetine (9.3), pregabalin (7.2), 
and   gabapentin (6.7). The IE for morphine is declining (from 
24.0 in 1994–1998), and is presently fueled to a great extent 
by controversy related to opioid addiction and unintentional 
overdose with the long-term treatment of chronic pain. The 
high IE value for gabapentin before 2009 was mostly due 
to the prolonged period of opinion formation that is typical 
with a new drug.
As far as the IC is concerned, in 2009–2013 only four 
of the 13 most popular drugs showed increases beyond 
that for the whole area of chronic pain: pregabalin (.100), 
oxycodone (.100), codeine (91), and duloxetine (77). The 
pregabalin and duloxetine values are mostly due to the fact 
Table 6 1974–2013 time course of changes (ic) for articles on chronic pain
Years All chronic pain articles Migraine-only articles PubMed “journal article” 
category Number IC (%) Number IC (%)
Number IC (%)
1974–1978 1,685 − 758 − 843,690 −
1979–1983 2,346 39 1,018 34 1,005,817 19
1984–1988 3,275 40 1,370 35 1,273,426 27
1989–1993 4,047 24 1,740 27 1,559,433 22
1994–1998 5,573 38 2,371 36 1,805,947 16
1999–2003 9,247 66 3,526 49 2,209,228 22
2004–2008 14,842 60 5,077 44 2,910,760 32
2009–2013 21,095 42 6,111 20 3,909,638 34
Abbreviation: ic, index of change.
Table 5 index of drug success, expressed as degree of decline in popularity of an old drug used for the same purpose
New family of drugs Disorder or  
disease
Old (supplanted) 
drug(s)
Decline of PI of supplanted drugs  
at different time intervals (years since 
new drug introduction) Group name  
(first drug)
Year of first  
drug approval
(5) (10) (15) (20) (25)
Triptans (sumatriptan) 1992 Migraine ergotamine OR 
dihydroergotamine
15% 45% 67% 73% –
PPis (omeprazole) 1990 gastroesophageal 
reflux
histamine 
h2 antagonists
32% 55% 71% – –
ace inhibitors (captopril) 1981 heart failure Digoxin 14% 29% 51% 74% 84%
Triazoles (itraconazole) 1994 (1984) Mycoses imidazoles 32% 42% 45% 55% –
Abbreviations: Pi, popularity index; PPis, proton-pump inhibitors; ace, angiotensin-converting enzyme.Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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that they are relatively new drugs. An increased IC with 
oxycodone and codeine is to a great extent related to the 
controversy associated with opioids in general.
index of ultimate success
The most important outcome of the introduction of a new 
drug is the slow decline of number of articles in medicobio-
logical professional journals about an old drug that previ-
ously was dominantly in use for the same purpose. Figure 1 
indicates that there was no such decline with major classes 
of old drugs used for the treatment of chronic pain (anti-
convulsants, antidepressants, or NSAIDs). On the contrary, 
opioids (not regarded as the best choice for the treatment of 
chronic pain in 1960–1980) began to gain popularity for this 
indication. Of all drugs used for the treatment of chronic 
pain, only triptans had the distinction of a positive IUS; 
however, that was for a limited migraine-specific indication. 
Ergotamine and dihydroergotamine, which were dominant 
for this purpose in 1974–1978, were actually supplanted by 
triptans in 1979–1983. At the same time, however, triptans 
did not supplant anticonvulsants or NSAIDs (Table 4).
Figure 2 illustrates changes in the popularity of compet-
ing drugs (new versus old) used in three different fields of 
pharmacotherapy: migraine, gastroesophageal reflux, and 
mycoses. Although the pattern looks the same – a very slow 
(10–20 years) process of a new drug supplanting one or 
more old drug – there was an important difference related 
to the mechanism of action between triptans and triazoles 
on the one hand and proton-pump inhibitors on the other. 
Proton-pump inhibitors supplanted histamine H2 inhibitors 
by offering a more effective and completely new mechanism 
of action with a new molecular target. Triptans and triazoles 
are very different from proton-pump inhibitors in this regard. 
Triptans, which displaced ergot alkaloids (ergotamine and 
dihydroergotamine) in the acute treatment of migraine, act on 
the same receptors (5-HT1B/1D) as ergot alkaloids,13 but more 
selectively, and thus are much less likely to cause adverse 
effects. This relationship between supplanting-supplanted 
groups of drugs for migraine is similar to what was observed 
in the triazoles–imidazoles competition in the treatment of 
mycoses (Figure 2). Both groups have the same molecular 
target in the fungal cell, but triazoles lack the human corti-
costeroid-suppression effect of imidazoles and have a broader 
antifungal spectrum.13 Therefore, of all new drugs developed 
over the past 35 years, only triptans reached the selected level 
of IUS – more than 50.   Nevertheless, the degree of novelty 
characterizing the molecular target of their pain-relieving 
action is not very high (compared with, eg, that of proton-
pump inhibitors, which supplanted   histamine H2 antagonists 
in the treatment of gastroesophageal reflux).
Rate of publication growth
The paucity of new successful drugs for the treatment of 
chronic pain cannot be explained by a lack of intellectual 
effort in the field. Table 6 indicates that for the past 35 years, 
publications on chronic pain grew exponentially, with 5-year 
increases (ranging from 24% to 60%) always higher than 
that in all medicobiological areas in combination. Overall, 
5-year publication productivity in the field of chronic pain 
grew from 2,346 in 1979–1983 to 21,095 in 2009–2013. If 
migraine-related publications (the only subfield of chronic 
pain with a positive IUS) are compared to publications in the 
whole chronic pain field (Table 6), it is clear that the rate of 
publication growth in the whole field was not slower than in 
the most successful subfield. Figure 3 represents the degree of 
change in the number of articles on migraine in general and 
in the number of articles on migraine and serotonin in com-
bination (a topic that culminated in the creation of triptans).24 
It is of interest that for two 5-year periods before the first 
publications on sumatriptan (1979–1983 and 1984–1988) 
there were no increases in the number of serotonin-related 
articles on migraine (in contrast to increases in publications 
on migraine in general). However, after the first publica-
tions on sumatriptan, the number of such articles increased 
dramatically (especially in 1989–1993).
These results indicate that increasing intellectual effort, 
including research, does not necessarily lead to the discovery 
of more effective drugs. Some correlation between the 
number of publications and probability of success exists, 
but it is probably very low. This may be comparable to the 
probability related to the role of sperm count in the chance 
of egg fertilization: increase in the sperm count from 20 to 
40 million only insignificantly increases the pregnancy rate 
with intrauterine insemination,25 while with intracytoplasmic 
sperm injection, a single sperm can be sufficient for egg 
fertilization. The author has previously discussed possible fac-
tors contributing to the apparent drought of novel analgesics 
in general.8 Undiscovered pain mechanisms or mechanisms 
that are already known but not yet appropriately exploited 
for drug development are likely the root of the problem. It is 
unlikely that usual increases in research effort significantly 
increase the probability of progress in the area of chronic pain. 
What kind of “intracytoplasmic sperm injection”   analogy 
may be used in pain research to facilitate the discovery of Journal of Pain Research 2014:7 submit your manuscript | www.dovepress.com
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new analgesics? Like with the chance of egg fertilization, not 
the number of researchers, but their individual qualities and 
specific features of their access to the process of drug design 
may be the keys to progress in this field.
The scientometric indices used to find signs of progress 
in the pharmacotherapy of chronic pain (PI, IC, IE, and IUS) 
are based on the link between the number of publications 
and progress in pharmacotherapy. This link is inherently 
weak. Its weakness is best illustrated by one of the most 
important findings of the present study: despite a nearly 
ninefold increase in the number of articles on chronic pain 
(from 1979–1983 to 2009–2013), there were no signs of 
really successful drugs in this field. In addition, this weakness 
is underlined by the fact that mere number of publications 
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does not differentiate between publications characterizing a 
drug in a positive or negative way. This has been illustrated 
in this paper, especially in relation to the opioids. Therefore, 
scientometric indices should be assessed in combination with 
results on drug effectiveness based on good-quality evidence 
obtained in randomized controlled trials, as was done in the 
discussion on opioid treatment of chronic nonmalignant pain 
(systematic reviews16–19). The scientometric indices used in 
the present study have different degrees of reliability in the 
demonstration of a drug’s progress: from the lower level with 
the PI and IC to the highest with the IUS.
In conclusion, very intensive effort over more than 
30 years produced an exponentially increasing number 
of publications on chronic pain, from a 5-year rate of 
2,346 articles in 1979–1983 to 21,095 articles in 2009–2013. 
However, despite this effort, the drugs most popular for the 
treatment of chronic pain actually belong to the old pharma-
cological classes: opioids, anticonvulsants, antidepressants, 
and NSAIDs. None of the studied drugs had a high IE in 
2009–2013. In addition, there were no drugs that changed 
the PI of opioids in chronic pain, despite limited opioid 
effectiveness (in addition to the serious problems of safety). 
The IUS was positive only with triptans in a relatively small 
area: the acute treatment of migraine.
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